Neil E Kay

List of Publications by Citations

356 papers	11,680 citations	57 h-index	104 g-index
369 ext. papers	13,309 ext. citations	4 avg, IF	5.76 L-index

#	Paper	IF	Citations
356	Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. *New England Journal of Medicine*, **2014**, 371, 213-23	59.2	1154
355	ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. *New England Journal of Medicine*, **2004**, 351, 893-901	59.2	754
354	Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. *American Journal of Hematology*, **1988**, 29, 152-63	7.1	346
353	Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. *New England Journal of Medicine*, **2019**, 381, 432-443	59.2	322
352	Diagnostic criteria for monoclonal B-cell lymphocytosis. *British Journal of Haematology*, **2005**, 130, 325-32	4.5	305
351	Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. *Blood*, **2009**, 114, 4441-50	2.2	260
350	Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. *Blood*, **2007**, 109, 405-11	2.2	258
349	Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. *Blood*, **2008**, 112, 1923-30	2.2	254
348	GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. *Blood*, **2019**, 133, 697-709	2.2	253
347	Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. *Blood*, **2017**, 129, 3419-3427	2.2	244
346	Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. *Journal of Clinical Oncology*, **2006**, 24, 4634-41	2.2	208
345	Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. *Blood*, **2014**, 124, 49-62	2.2	202
344	Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. *Blood*, **2004**, 103, 1202-10	2.2	195
343	Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. *Blood*, **2010**, 115, 1755-64	2.2	181
342	VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. *Blood*, **2004**, 104, 788-94	2.2	177
341	Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. *British Journal of Haematology*, **2003**, 121, 287-95	4.5	176
340	Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. *British Journal of Haematology*, **2001**, 115, 854-61	4.5	163

339	Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. *Blood*, **2013**, 122, 1891-9	2.2	157
338	Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. *British Journal of Haematology*, **2013**, 162, 774-82	4.5	151
337	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. *Nature Genetics*, **2013**, 45, 868-76	36.3	147
336	Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. *Leukemia and Lymphoma*, **2008**, 49, 49-56	1.9	146
335	De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. *Blood*, **2009**, 114, 957-64	2.2	134
334	CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. *British Journal of Haematology*, **2008**, 140, 537-46	4.5	131
333	Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. *Cancer*, **2007**, 109, 2291-8	6.4	131
332	How we treat Richter syndrome. *Blood*, **2014**, 123, 1647-57	2.2	116
331	LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. *Blood*, **2010**, 116, 2975-83	2.2	115
330	Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. *Blood*, **2009**, 113, 5568-74	2.2	112
329	Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. *Journal of Clinical Oncology*, **2009**, 27, 3959-63	2.2	109
328	Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. *Blood*, **2011**, 117, 1911-6	2.2	102
327	Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG. *Clinical Cancer Research*, **2009**, 15, 1250-8	12.9	102
326	How I treat autoimmune hemolytic anemia. *Blood*, **2017**, 129, 2971-2979	2.2	100
325	Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. *Journal of Clinical Oncology* , **2012**, 30, 2483-91	2.2	100
324	Identification of a global gene expression signature of B-chronic lymphocytic leukemia. *Molecular Cancer Research*, **2003**, 1, 346-61	6.6	100
323	Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. *Blood*, **2010**, 116, 2984-93	2.2	98
322	The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. *Blood*, **2011**, 117, 1928-37	2.2	97

321	B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. *Blood*, **2009**, 113, 4188-96	2.2	91
320	Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. *Cancer*, **2010**, 116, 4777-87	6.4	91
319	The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. *British Journal of Haematology*, **2008**, 141, 615-21	4.5	84
318	Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. *Leukemia and Lymphoma*, **2007**, 48, 2412-7	1.9	82
317	Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin □4-□1 (VLA-4) with natalizumab can overcome this resistance. *British Journal of Haematology*, **2011**, 155, 53-64	4.5	80
316	Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients. *Blood*, **2001**, 98, 23-8	2.2	78
315	Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels. *Journal of Oncology Practice*, **2015**, 11, 252-8	3.1	77
314	High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. *Blood*, **2016**, 128, 2931-2940	2.2	75
313	Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). *Blood*, **2013**, 121, 4137-41	2.2	72
312	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). *Leukemia and Lymphoma*, **2017**, 58, 1630-1639	1.9	71
311	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. *Nature Communications*, **2016**, 7, 10933	17.4	70
310	Autoimmune complications in chronic lymphocytic leukaemia (CLL). *Best Practice and Research in Clinical Haematology*, **2010**, 23, 47-59	4.2	69
309	The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells. *PLoS ONE*, **2013**, 8, e83830	3.7	67
308	Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. *British Journal of Haematology*, **2009**, 147, 471-83	4.5	65
307	Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. *Journal of Clinical Oncology*, **2021**, 39, 3441-3452	2.2	65
306	Validation of a new prognostic index for patients with chronic lymphocytic leukemia. *Cancer*, **2009**, 115, 363-72	6.4	64
305	Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. *Blood*, **2012**, 120, 843-6	2.2	63
304	Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. *Cancer*, **2008**, 113, 2110-8	6.4	62

303	Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. *Leukemia and Lymphoma*, **2009**, 50, 1261-8	1.9	60
302	The efficacy of ibrutinib in the treatment of Richter syndrome. *Blood*, **2015**, 125, 1676-8	2.2	57
301	Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. *Blood*, **2009**, 113, 535-7	2.2	57
300	Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch". *Leukemia Research*, **2007**, 31, 899-906	2.7	57
299	Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma. *American Journal of Hematology*, **2015**, 90, 334-8	7.1	56
298	Circulating Blood B Cells in Multiple Myeloma: Analysis and Relationship to Circulating Clonal Cells and Clinical Parameters in a Cohort of Patients Entered on the Eastern Cooperative Oncology Group Phase III E9486 Clinical Trial. *Blood*, **1997**, 90, 340-345	2.2	55
297	Chronic lymphocytic leukemia. *Hematology American Society of Hematology Education Program*, **2002**, 2002, 193-213	3.1	54
296	Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience. *Haematologica*, **2015**, 100, 1180-8	6.6	53
295	Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors. *Clinical Cancer Research*, **2015**, 21, 2115-26	12.9	51
294	Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. *Blood*, **2014**, 124, 42-8	2.2	50
293	Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families. *British Journal of Haematology*, **2010**, 151, 152-8	4.5	50
292	Large-scale analysis of DNA methylation in chronic lymphocytic leukemia. *Epigenomics*, **2009**, 1, 39-61	4.4	49
291	Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes. *Cancer*, **2015**, 121, 2883-91	6.4	47
290	Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone. *Leukemia and Lymphoma*, **2010**, 51, 620-7	1.9	47
289	The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma. *Cancer*, **1999**, 86, 957-968	6.4	46
288	Interleukin 4 content in chronic lymphocytic leukaemia (CLL) B cells and blood CD8+ T cells from B-CLL patients: impact on clonal B-cell apoptosis. *British Journal of Haematology*, **2001**, 112, 760-7	4.5	45
287	Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia. *Blood*, **2015**, 125, 492-8	2.2	44
286	Analysis of blood T-cell cytokine expression in B-chronic lymphocytic leukaemia: evidence for increased levels of cytoplasmic IL-4 in resting and activated CD8 T cells. *British Journal of Haematology*, **1997**, 96, 733-5	4.5	44

285	The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients. *American Journal of Hematology*, **2016**, 91, 1090-1095	7.1	43
284	The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia. *Seminars in Oncology*, **2006**, 33, 174-85	5.5	42
283	Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL). *Cancer*, **2013**, 119, 3788-96	6.4	40
282	A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912). *Blood*, **2018**, 132, LBA-4-LBA-4	2.2	40
281	Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine. *Blood*, **2005**, 105, 2099-106	2.2	38
280	T-cell subpopulations in multiple myeloma: correlation with clinical disease status. *British Journal of Haematology*, **1981**, 49, 629-34	4.5	38
279	Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. *British Journal of Haematology*, **2017**, 178, 394-402	4.5	37
278	Real-world clinical experience in the Connect chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. *British Journal of Haematology*, **2016**, 175, 892-903	4.5	37
277	IL-4 biology: impact on normal and leukemic CLL B cells. *Leukemia and Lymphoma*, **2003**, 44, 897-903	1.9	36
276	Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma. *International Journal of Molecular Epidemiology and Genetics*, **2011**, 2, 95-113	0.9	35
275	Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. *EBioMedicine*, **2015**, 2, 572-82	8.8	34
274	Progressive but previously untreated CLL patients with greater array CGH complexity exhibit a less durable response to chemoimmunotherapy. *Cancer Genetics and Cytogenetics*, **2010**, 203, 161-8		33
273	Dysregulated angiogenesis in B-chronic lymphocytic leukemia: morphologic, immunohistochemical, and flow cytometric evidence. *Diagnostic Pathology*, **2008**, 3, 16	3	32
272	Identification of recurrent truncated DDX3X mutations in chronic lymphocytic leukaemia. *British Journal of Haematology*, **2015**, 169, 445-8	4.5	31
271	Loss of TP53 is due to rearrangements involving chromosome region 17p10 approximately p12 in chronic lymphocytic leukemia. *Cancer Genetics and Cytogenetics*, **2006**, 167, 177-81		31
270	Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. *Haematologica*, **2020**, 105, 765-773	6.6	31
269	Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. *Leukemia and Lymphoma*, **2017**, 58, 1376-1383	1.9	30
268	Extramedullary chronic lymphocytic leukemia: systematic analysis of cases reported between 1975 and 2012. *Leukemia Research*, **2014**, 38, 299-303	2.7	30

267	Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). *Cancer*, **2012**, 118, 1827-37	6.4	30
266	Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia: a phase I/II study by the Eastern Cooperative Oncology Group study E1488. *Leukemia and Lymphoma*, **2004**, 45, 79-84	1.9	30
265	Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia. *Cancer*, **2010**, 116, 2180-7	6.4	29
264	Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. *Leukemia and Lymphoma*, **2019**, 60, 2712-2719	1.9	28
263	Incidence of chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis using the 2008 guidelines. *Cancer*, **2014**, 120, 2000-5	6.4	27
262	Analytical Considerations in Nanoscale Flow Cytometry of Extracellular Vesicles to Achieve Data Linearity. *Thrombosis and Haemostasis*, **2018**, 118, 1612-1624	7	26
261	Sphingosine Kinase-1 Protects Multiple Myeloma from Apoptosis Driven by Cancer-Specific Inhibition of RTKs. *Molecular Cancer Therapeutics*, **2015**, 14, 2303-12	6.1	25
260	Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. *British Journal of Haematology*, **2018**, 183, 421-427	4.5	25
259	The impact of race, ethnicity, age and sex on clinical outcome in chronic lymphocytic leukemia: a comprehensive Surveillance, Epidemiology, and End Results analysis in the modern era. *Leukemia and Lymphoma*, **2014**, 55, 2778-84	1.9	23
258	T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93. *British Journal of Haematology*, **1998**, 100, 459-63	4.5	22
257	Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial. *Blood*, **2019**, 134, 33-33	2.2	22
256	The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. *Cancer Medicine*, **2020**, 9, 3390-3399	4.8	19
255	Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis. *British Journal of Haematology*, **2014**, 164, 146-50	4.5	17
254	Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy. *Blood*, **2021**, 137, 216-231	2.2	17
253	Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study. *American Journal of Hematology*, **2017**, 92, 759-763	7.1	16
252	Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry. *Clinical Lymphoma, Myeloma and Leukemia*, **2018**, 18, 114-124.e2	2	16
251	Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. *Blood*, **2019**, 134, 688-698	2.2	16
250	Combination Chemotherapy with Pentostatin, Cyclophosphamide and Rituximab Induces High Rate of Remissions Including Complete Responses and Achievement of Minimal Residual Disease in Previously Untreated B-Chronic Lymphocytic Leukemia.. *Blood*, **2004**, 104, 339-339	2.2	16

249	Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. *Leukemia Research*, **2020**, 97, 106432	2.7	16
248	CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia. *British Journal of Haematology*, **2017**, 178, 99-105	4.5	15
247	Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. *Blood*, **2018**, 131, 2541-2551	2.2	15
246	Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial. *Lancet Haematology,the*, **2016**, 3, e407-14	14.6	15
245	Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL): An Analysis of a Large Cohort of Patients Treated in Routine Clinical Practice. *Blood*, **2015**, 126, 2935-2935	2.2	15
244	PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485). *Blood*, **2015**, 126, 834-834	2.2	15
243	Bone marrow hematopoietic dysfunction in untreated chronic lymphocytic leukemia patients. *Leukemia*, **2019**, 33, 638-652	10.7	15
242	Tumor suppressor genes and clonal evolution in B-CLL. *Leukemia and Lymphoma*, **1995**, 18, 41-9	1.9	14
241	Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia. *British Journal of Haematology*, **2009**, 146, 660-4	4.5	13
240	Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia. *Leukemia Research*, **2007**, 31, 1737-40	2.7	13
239	Purine analogue-based chemotherapy regimens for patients with previously untreated B-chronic lymphocytic leukemia. *Seminars in Hematology*, **2006**, 43, S50-4	4	13
238	Differential effect of hemodialysis membranes on human lymphocyte natural killer function. *Artificial Organs*, **1987**, 11, 165-7	2.6	13
237	The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL). *Vaccine*, **2021**, 39, 1122-1130	4.1	13
236	N9986: a phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia. *Leukemia and Lymphoma*, **2009**, 50, 588-92	1.9	12
235	Comprehensive management of the CLL patient: a holistic approach. *Hematology American Society of Hematology Education Program*, **2007**, 324-31	3.1	12
234	Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia. *Molecular Therapy*, **2021**, 29, 1529-1540	11.7	12
233	Tris (dibenzylideneacetone) dipalladium: a small-molecule palladium complex is effective in inducing apoptosis in chronic lymphocytic leukemia B-cells. *Leukemia and Lymphoma*, **2016**, 57, 2409-16	1.9	12
232	Chronic lymphocytic leukemia international prognostic index: a systematic review and meta-analysis. *Blood*, **2018**, 131, 365-368	2.2	11

231	Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach. *Leukemia and Lymphoma*, **2011**, 52, 1425-34	1.9	11
230	A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cells. *Leukemia Research*, **2005**, 29, 1009-18	2.7	11
229	The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor. *Haematologica*, **2020**, 105, 2675-2678	6.6	11
228	Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice. *Leukemia and Lymphoma*, **2020**, 61, 2383-2388	1.9	11
227	Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi-institutional study. *American Journal of Hematology*, **2016**, 91, 687-91	7.1	11
226	IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes. *American Journal of Hematology*, **2019**, 94, 338-345	7.1	11
225	KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival. *Leukemia*, **2019**, 33, 2111-2115	10.7	10
224	Chemoimmunotherapy Is Not Dead Yet in Chronic Lymphocytic Leukemia. *Journal of Clinical Oncology*, **2017**, 35, 2989-2992	2.2	10
223	SphK1 inhibitor potentiates the anti-cancer effect of EGCG on leukaemia cells. *British Journal of Haematology*, **2017**, 178, 155-158	4.5	10
222	Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. *Leukemia and Lymphoma*, **2013**, 54, 476-82	1.9	10
221	Prognostic factors in chronic lymphocytic leukemia. *Current Hematologic Malignancy Reports*, **2007**, 2, 49-55	4.4	10
220	Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis. *Haematologica*, **2018**, 103, e237-e240	6.6	9
219	Cumulative experience and long term follow-up of pentostatin-based chemoimmunotherapy trials for patients with chronic lymphocytic leukemia. *Expert Review of Hematology*, **2018**, 11, 337-349	2.8	9
218	Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemia. *American Journal of Hematology*, **2016**, 91, 677-80	7.1	9
217	Sequential phenotyping of myeloma patients on chemotherapy: persistence of activated T-cells and natural killer cells. *Leukemia and Lymphoma*, **1995**, 16, 351-4	1.9	9
216	Targeting Cancer Associated Fibroblasts in the Bone Marrow Prevents Resistance to Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma. *Blood*, **2019**, 134, 865-865	2.2	9
215	Monoclonal B-cell lymphocytosis: update on diagnosis, clinical outcome, and counseling. *Clinical Advances in Hematology and Oncology*, **2013**, 11, 720-9	0.6	9
214	Renal insufficiency is an independent prognostic factor in patients with chronic lymphocytic leukemia. *Haematologica*, **2017**, 102, e22-e25	6.6	8

213	Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings. *American Journal of Hematology*, **2017**, 92, 1362-1369	7.1	8
212	Chronic lymphocytic leukemia: biology and current treatment. *Current Oncology Reports*, **2007**, 9, 345-52	6.3	8
211	Controversies in the front-line management of chronic lymphocytic leukemia. *Leukemia Research*, **2008**, 32, 679-88	2.7	8
210	Chronic lymphocytic leukemia: current and emerging treatment approaches. *Clinical Advances in Hematology and Oncology*, **2006**, 4, 1-10; quiz 11-2	0.6	8
209	Critical signal transduction pathways in CLL. *Advances in Experimental Medicine and Biology*, **2013**, 792, 215-39	3.6	7
208	Early progression of disease as a predictor of survival in chronic lymphocytic leukemia. *Blood Advances*, **2017**, 1, 2433-2443	7.8	7
207	The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia. *Clinical Medicine Insights: Oncology*, **2011**, 5, 45-53	1.8	7
206	Proteomic Analysis of Chronic Lymphocytic Leukemia Cells Identifies Vimentin as a Novel Prognostic Factor for Aggressive Disease.. *Blood*, **2005**, 106, 707-707	2.2	7
205	The Importance of Pharmacovigilance during Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice. *Blood*, **2015**, 126, 717-717	2.2	7
204	PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485). *Blood*, **2016**, 128, 4392-4392	2.2	7
203	A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia. *Oncotarget*, **2016**, 7, 78269-78280	3.3	7
202	Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL). *Leukemia*, **2021**, 35, 239-244	10.7	7
201	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes. *Annals of Hematology*, **2021**, 100, 143-155	3	7
200	Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic index. *American Journal of Hematology*, **2020**, 95, 906-917	7.1	6
199	Ibrutinib-Based Therapy Improves Anti-Tumor T Cell Killing Function Allowing Effective Pairing with Anti-PD-L1 Immunotherapy Compared to Traditional FCR Chemoimmunotherapy; Implications for Therapy and Correlative Immune Functional Data from the Phase III E1912 Trial. *Blood*, **2018**, 132, 236-236	2.2	6
198	A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. *Haematologica*, **2020**, 105, 1613-1620	6.6	6
197	Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. *Blood Cancer Discovery*, **2021**, 2, 54-69	7	6
196	Role of long non-coding RNAs in disease progression of early stage unmutated chronic lymphocytic leukemia. *Oncotarget*, **2019**, 10, 60-75	3.3	5

195	Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment. *European Journal of Haematology*, **2018**, 101, 703	3.8	5
194	Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants. *Cancer Genetics*, **2014**, 207, 19-30	2.3	5
193	Activation of human peripheral blood T cells does not lead to increased P-glycoprotein expression. *Journal of Clinical Immunology*, **1999**, 19, 239-46	5.7	5
192	Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition Is Mechanistically Supported By a Novel Direct Interaction of GM-CSF with Activated Carts. *Blood*, **2019**, 134, 3868-3868	2.2	5
191	Cyclophosphamide Remains An Important Component of Treatment in CLL Patients Receiving Pentostatin and Rituximab Based Chemoimmunotherapy. *Blood*, **2008**, 112, 43-43	2.2	5
190	Hodgkin Transformation Of Chronic Lymphocytic Leukemia (CLL): Mayo Clinic Experience. *Blood*, **2013**, 122, 1642-1642	2.2	5
189	Atrial Fibrillation in Patients with Chronic Lymphocytic Leukemia (CLL). *Blood*, **2015**, 126, 2950-2950	2.2	5
188	Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. *American Journal of Hematology*, **2020**, 95, E57-E60	7.1	5
187	Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. *Oncologist*, **2020**, 25, 974-980	5.7	5
186	Community-based phase II trial of PCR for CLL/SLL patients. *Cancer Biotherapy and Radiopharmaceuticals*, **2007**, 22, 713-4; author reply 715-7	3.9	4
185	T-cell abnormalities in patients with chronic lymphocytic leukemia. *Leukemia and Lymphoma*, **2006**, 47, 1197-8	1.9	4
184	Targeting Cancer-Associated Fibroblasts in the Bone Marrow Prevents Resistance to CART-Cell Therapy in Multiple Myeloma.. *Blood*, **2022**,	2.2	4
183	Targeting of CD19 By Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity in Vitro. *Blood*, **2019**, 134, 2859-2859	2.2	4
182	Alemtuzumab and Rituximab for Therapy of Patents with Early Stage High Risk CLL: Report of a Planned Interim Analysis.. *Blood*, **2006**, 108, 2829-2829	2.2	4
181	Outcomes Of Chronic Lymphocytic Leukemia Patients With Richter Syndrome. *Blood*, **2013**, 122, 4179-4179	2.2	4
180	Disease Progression and Complications Are the Main Cause of Death in Patients with Chronic Lymphocytic Leukemia (CLL) Independent of Age and Comorbidities at Diagnosis. *Blood*, **2015**, 126, 5265-5265	2.2	4
179	Skin Cancers Among Chronic Lymphocytic Leukemia (CLL) Patients - the Effect of UV Radiation and CLL Clinical Characteristics. *Blood*, **2016**, 128, 4772-4772	2.2	4
178	Circulating Blood B Cells in Multiple Myeloma: Analysis and Relationship to Circulating Clonal Cells and Clinical Parameters in a Cohort of Patients Entered on the Eastern Cooperative Oncology Group Phase III E9486 Clinical Trial. *Blood*, **1997**, 90, 340-345	2.2	4

177	Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. *American Journal of Hematology*, **2021**, 97, 90	7.1	4
176	Pathogenesis of Impaired Cellular Immune Function in CLL **2004**, 109-121		4
175	Chronic lymphocytic leukemia (CLL) risk is mediated by multiple enhancer variants within CLL risk loci. *Human Molecular Genetics*, **2020**, 29, 2761-2774	5.6	4
174	The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL. *Blood*, **2021**, 138, 149-159	2.2	4
173	Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families. *Blood*, **2021**, 137, 2046-2056	2.2	4
172	Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. *Blood Cancer Journal*, **2021**, 11, 86	7	4
171	Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia. *Journal of Hematology and Oncology*, **2021**, 14, 17	22.4	4
170	The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites. *Blood Advances*, **2020**, 4, 1407-1418	7.8	3
169	Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect CLL cohort study. *Leukemia and Lymphoma*, **2018**, 59, 2327-2335	1.9	3
168	Combination therapies for previously untreated CLL. *Lancet, The*, **2007**, 370, 197-198	40	3
167	MBL and MoBL Response to Ziegler-Heitbrock. *British Journal of Haematology*, **2005**, 130, 795-796	4.5	3
166	Genetic Determinants and Evolutionary History of Richter's Syndrome. *Blood*, **2020**, 136, 47-48	2.2	3
165	GM-CSF Blockade during Chimeric Antigen Receptor T Cell Therapy Reduces Cytokine Release Syndrome and Neurotoxicity and May Enhance Their Effector Functions. *Blood*, **2018**, 132, 961-961	2.2	3
164	A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). *Blood*, **2019**, 134, 4306-4306	2.2	3
163	ZAP-70 Expression Associated with Activation in Normal Human B Cells and B Cell Chronic Lymphocytic Leukemia.. *Blood*, **2004**, 104, 2794-2794	2.2	3
162	Frequency of Clonal Evolution by FISH in Untreated, Early Stage Patients with CLL: A Prospective, Longitudinal Study with Long Clinical Follow-Up.. *Blood*, **2005**, 106, 2098-2098	2.2	3
161	Chronic Lymphocytic Leukemia Patients with IGHV Genes Carrying Only Silent Mutations Have A Longer Time From Diagnosis to Initial Therapy Than Patients Expressing B-Cell Receptors with No Somatic Mutations. *Blood*, **2011**, 118, 288-288	2.2	3
160	Pure Red Cell Aplasia (PRCA) in Chronic Lymphocytic Leukemia (CLL): Etiology, Therapy, and Outcomes. *Blood*, **2015**, 126, 4169-4169	2.2	3

159	Outcomes of Ibrutinib Therapy By Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2). *Blood*, **2016**, 128, 2041-2041	2.2	3
158	Comparative Evaluation of Prognostic Factors That Assess the Natural History of Chronic Lymphocytic Leukemia. *Blood*, **2016**, 128, 968-968	2.2	3
157	Prevalence of Low Count (LC) Monoclonal B Cell Lymphocytosis (MBL) and Serious Infections in a Population-Based Cohort of U.S. Adults Participating in a Large Bio-Repository. *Blood*, **2017**, 130, 831-831	2.2	3
156	Chronic lymphocytic leukemia B-cell-derived TNF impairs bone marrow myelopoiesis. *IScience*, **2021**, 24, 101994	6.1	3
155	Early intervention in asymptomatic chronic lymphocytic leukemia. *Clinical Advances in Hematology and Oncology*, **2021**, 19, 92-103	0.6	3
154	High prevalence of monoclonal gammopathy among patients with warm autoimmune hemolytic anemia. *American Journal of Hematology*, **2017**, 92, E164-E166	7.1	2
153	Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. *Blood Cancer Journal*, **2019**, 9, 59	7	2
152	CGH protocols: chronic lymphocytic leukemia. *Methods in Molecular Biology*, **2013**, 973, 87-98	1.4	2
151	Circulating endothelial cells in chronic lymphocytic leukemia: more evidence of disturbed angiogenesis. *Leukemia and Lymphoma*, **2009**, 50, 8-9	1.9	2
150	BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression. *Blood*, **2019**, 134, 3050-3050	2.2	2
149	The Pentostatin, Cyclophosphamide, and Rituximab Regimen (PCR) Is Highly Active and Well Tolerated Regardless of Patient Age, Creatinine Clearance, and Performance Status: Analysis of a Multi-Center Phase II Trial.. *Blood*, **2006**, 108, 36-36	2.2	2
148	Characteristics of Familial CLL Evaluated in the CLL Research Consortium Cohort. *Blood*, **2008**, 112, 3125-3125	2.2	2
147	Family-Associated Monoclonal B Lymphocytosis Is Commonly Oligoclonal and Expresses Markers Associated with Adverse Risk in CLL. *Blood*, **2008**, 112, 3144-3144	2.2	2
146	Lenalidomide Consolidation Appears to Prolong Time to Retreatment After First-Line Chemoimmunotherapy for Patients with Previously Untreated CLL,. *Blood*, **2011**, 118, 3899-3899	2.2	2
145	Hypogammaglobulinemia In Patients With Previously Untreated Chronic Lymphocytic Leukemia: Clinical Correlates and Outcomes. *Blood*, **2013**, 122, 4178-4178	2.2	2
144	Delineation of clinical and biological factors associated with cutaneous squamous cell carcinoma among patients with chronic lymphocytic leukemia. *Journal of the American Academy of Dermatology*, **2020**, 83, 1581-1589	4.5	2
143	Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemia. *Scientific Reports*, **2021**, 11, 8318	4.9	2
142	Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity. *Cancer Immunology Research*, **2021**, 9, 1035-1046	12.5	2

141	Chronic lymphocytic leukemia in 2020: a surfeit of riches?. *Leukemia*, **2020**, 34, 1979-1983	10.7	1
140	Reply to S. Opat et al. *Journal of Clinical Oncology*, **2017**, 35, 4094-4095	2.2	1
139	A novel method for analysis of human T cell repertoires by real-time PCR. *Journal of Immunological Methods*, **2014**, 412, 24-34	2.5	1
138	Predicting clinical outcome in B-chronic lymphocytic leukemia. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2012**, 394-8	7.1	1
137	Reply to R.S. Go. *Journal of Clinical Oncology*, **2009**, 27, e45-e45	2.2	1
136	Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies. *Leukemia and Lymphoma*, **2011**, 52, 374-86	1.9	1
135	Vesicular Stomatitis Virus (VSV) Engineered to Express CD19 Stimulates Anti-CD19 Chimeric Antigen Receptor Modified T Cells and Promotes Their Anti-Tumor Effects. *Blood*, **2020**, 136, 30-31	2.2	1
134	Distinct Gene Expression Signatures in Patients with Richter's Syndrome and Chronic Lymphocytic Leukemia with Prior Exposure to Ibrutinib. *Blood*, **2020**, 136, 30-31	2.2	1
133	Genomic Profiling Reveals Molecular Heterogeneity in Patients with Richter's Syndrome (RS) and Progressive Chronic Lymphocytic Leukemia (CLL). *Blood*, **2020**, 136, 16-17	2.2	1
132	Immunogenicity of a Recombinant Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia. *Blood*, **2020**, 136, 49-50	2.2	1
131	Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?. *Blood Cancer Journal*, **2022**, 12, 18	7	1
130	CLL update 2022: A continuing evolution in care.. *Blood Reviews*, **2022**, 100930	11.1	1
129	Comprehensive Management of the CLL Patient: A Holistic Approach. *Hematology American Society of Hematology Education Program*, **2007**, 2007, 324-331	3.1	1
128	Axl-RTK Inhibition Modulates T Cell Functions and Synergizes with Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies. *Blood*, **2018**, 132, 728-728	2.2	1
127	Development of a Sensitive and Efficient Reporter Platform for the Detection of Chimeric Antigen Receptor T Cell Expansion, Trafficking, and Toxicity. *Blood*, **2019**, 134, 53-53	2.2	1
126	Circulating Extracellular Vesicles Induce Chimeric Antigen Receptor T Cell Dysfunction in Chronic Lymphocytic Leukemia (CLL). *Blood*, **2019**, 134, 679-679	2.2	1
125	Venetoclax Has Modest Efficacy in the Treatment of Patients with Relapsed T-Cell Prolymphocytic Leukemia. *Blood*, **2020**, 136, 39-40	2.2	1
124	Hypoxia Inducible Factor-1 is over Expressed in CLL B Cells Because of an Impaired Proteasome Pathway Associated with Defective Interaction with von Hippel-Landau Protein.. *Blood*, **2005**, 106, 2115-2115	2.2	1

123	The Green Tea Extract Epigallocatechin Induces In Vitro Cell Death in Primary Human Lymphoma Cells through an ROS Dependent Mechanism.. *Blood*, **2006**, 108, 234-234	2.2	1
122	Smudge Cells on Routine Blood Smear Predict Clinical Outcome in Chronic Lymphocytic Leukemia: A Universally Available Prognostic Test.. *Blood*, **2006**, 108, 2785-2785	2.2	1
121	Alemtuzumab and Rituximab for Initial Treatment of High Risk, Early Stage Chronic Lymphocytic Leukemia (CLL).. *Blood*, **2007**, 110, 2050-2050	2.2	1
120	CD5+ Chronic B-Cell Lymphoproliferative Disorders Could Contain a Novel Disease Entity.. *Blood*, **2008**, 112, 2065-2065	2.2	1
119	Pentostatin, Alemtuzumab, and Low Dose Rituximab Is Effective Therapy for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL). *Blood*, **2011**, 118, 1790-1790	2.2	1
118	Resistance to Complement Dependent Cytotoxicity in CLL Cells From Patients Treated with Ofatumumab. *Blood*, **2011**, 118, 2836-2836	2.2	1
117	Axl Receptor Tyrosine Kinase Signaling Pathway and the p53 Tumor Suppressor Protein Exist In A Novel Regulatory Loop In B-Cell Chronic Lymphocytic Leukemia Cells. *Blood*, **2011**, 118, 799-799	2.2	1
116	High-Level Expression of ROR1 Associates with Early Disease Progression in Patients with Chronic Lymphocytic Leukemia. *Blood*, **2015**, 126, 1713-1713	2.2	1
115	Characteristics and Outcome of Direct Antiglobulin Test-Negative Hemolytic Anemia: A Case Series. *Blood*, **2016**, 128, 2451-2451	2.2	1
114	Role of Lncrnas in Early Stage Immunoglobulin Heavy Chain Variable Region (IGHV) Unmutated CLL Disease Progression. *Blood*, **2016**, 128, 4364-4364	2.2	1
113	Serum B-cell maturation antigen as a prognostic marker for untreated chronic lymphocytic leukemia.. *Journal of Clinical Oncology*, **2019**, 37, 7525-7525	2.2	1
112	Leukemic B Cells from CD38 Positive but Not CD38 Negative B-CLL Patients Express Heightened Levels of Cell Cycle Related Genes.. *Blood*, **2004**, 104, 4809-4809	2.2	1
111	Tumor Cells Resistant to Alemtuzumab Complement Mediated Cytotoxicity in Patients with High Risk Previously Untreated Early Stage CLL: A Possible Mechanism of Treatment Failure.. *Blood*, **2005**, 106, 2973-2973	2.2	1
110	PD-1 Overexpression in Richter's Transformation (RT) and Aggressive Chronic Lymphocytic Leukemia (CLL) after Progression on Ibrutinib Increases Bcl-2 Expression Via Akt/mTOR Pathway. *Blood*, **2018**, 132, 586-586	2.2	1
109	Factors That Influence Treatment Decision-Making: Perspectives of 1147 Chronic Lymphocytic Leukemia (CLL) Patients in the United States. *Blood*, **2018**, 132, 4414-4414	2.2	1
108	Liver Biopsy in Patients with Chronic Lymphocytic Leukemia: Indications and Pathological Findings. *Blood*, **2016**, 128, 5592-5592	2.2	1
107	Cytogenetic Analysis of Normal Human B Cells Following CpG Stimulation: Implications for Interpretation of CpG Induced CLL Metaphase Analysis. *Blood*, **2008**, 112, 3124-3124	2.2	1
106	De Novo Deletion 17p13.1 Chronic Lymphocytic Leukemia Shows Significant Clinical Heterogeneity: The MD Anderson/Mayo Clinic Experience.. *Blood*, **2008**, 112, 1056-1056	2.2	1

105	Overexpression of the LEF-1 and TCF4 Transcription Factors in B-CLL: Further Evidence for a Role of the Wnt Signaling Pathway in B-CLL Biology and Leukemogenesis. *Blood*, **2008**, 112, 544-544	2.2	1
104	Longitudinal health-related quality of life in first-line treated patients with chronic lymphocytic leukemia: Results from the Connect CLL Registry. *EJHaem*, **2020**, 1, 188-198	0.9	1
103	Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. *Blood Cancer Journal*, **2021**, 11, 47	7	1
102	The prognostic significance of del6q23 in chronic lymphocytic leukemia. *American Journal of Hematology*, **2021**, 96, E203-E206	7.1	1
101	SIRT3 overexpression and epigenetic silencing of catalase regulate ROS accumulation in CLL cells activating AXL signaling axis. *Blood Cancer Journal*, **2021**, 11, 93	7	1
100	B-cell prolymphocytic leukemia has 3 subsets. *Blood*, **2019**, 134, 1777-1778	2.2	1
99	Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans. *Leukemia*, **2021**,	10.7	1
98	Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903). *Acta Haematologica*, **2019**, 142, 224-232	2.7	0
97	Favorable Modulation of Chimeric Antigen Receptor T Cells Safety and Efficacy By the Non-Covalent BTK Inhibitor Vecabrutinib. *Blood*, **2021**, 138, 906-906	2.2	0
96	Differential transcriptomic profiling in ibrutinib-naïve versus ibrutinib-resistant Richter syndrome. *Hematological Oncology*, **2021**,	1.3	0
95	Aspirin and other nonsteroidal anti-inflammatory drugs, statins and risk of non-Hodgkin lymphoma. *International Journal of Cancer*, **2021**, 149, 535-545	7.5	0
94	Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index. *Blood Cancer Journal*, **2021**, 11, 140	7	0
93	Usefulness of Risk Stratification in the Treatment of Patients with Chronic Lymphocytic Leukemia. *Clinical Leukemia*, **2008**, 2, 46-54		
92	Pre-Existing T Cell Subsets Determine Anti-PD1 Blockade Response in Richter's Transformation. *Blood*, **2020**, 136, 42-43	2.2	
91	Polygenic Risk Score and Risk of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and MBL Subtypes. *Blood*, **2020**, 136, 35-36	2.2	
90	Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Chronic Lymphocytic Leukemia Who Are 80 Years of Age or Older. *Blood*, **2020**, 136, 26-27	2.2	
89	Identification of a Novel Role for PD-1 Signaling in Promotion Tumor Proliferation in B-Cell Lymphoma. *Blood*, **2020**, 136, 10-12	2.2	
88	Axl-RTK Inhibition Modulates Monocyte Immune Response to Enhance the Anti-Tumor Effects of CD19 Redirected Chimeric Antigen Receptor T Cells in Preclinical Models. *Blood*, **2020**, 136, 28-29	2.2	

87	Central Nervous System (CNS) Involvement of Richter Transformation: A Single Center Experience. *Blood*, **2020**, 136, 3-4	2.2
86	Impact of Deletion6q23 Identified By FISH in Patients with Chronic Lymphocytic Leukemia. *Blood*, **2020**, 136, 12-13	2.2
85	Targeting Aberrant Chromatin in Chronic Lymphocytic Leukemia. *Blood*, **2020**, 136, 1-1	2.2
84	Use of Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation (AF) in Patients with Chronic Lymphocytic Leukemia (CLL). *Blood*, **2020**, 136, 50-51	2.2
83	Optimized Inhibition of GM-CSF in Preclinical Models of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. *Blood*, **2021**, 138, 2777-2777	2.2
82	Molecular Mechanisms Involved in Homing and Migration of B-Chronic Lymphocytic Leukemia (CLL) in Response to CXCR4 Stimulation and Downstream Activation of the PI3K Pathway.. *Blood*, **2004**, 104, 1909-1909	2.2
81	Associations of DNA Repair Gene Polymorphisms in XRCC1 and ERCC2 with Clinical Outcome in ECOG Trial E9486.. *Blood*, **2004**, 104, 1475-1475	2.2
80	CLL B Cell Interaction with Bone Biopsy Generated Marrow Stromal Elements Enhances Their Apoptosis Resistance in Association with an Angiogenic Switch.. *Blood*, **2004**, 104, 1914-1914	2.2
79	Elevated BLyS Levels in Patients with Familial and Sporadic B-CLL: Correlation with BLyS Polymorphisms.. *Blood*, **2004**, 104, 964-964	2.2
78	Loss of p53 Is Due to Rearrangements in a ~6,400 kb Region of Low Copy Repeats near the Centromere of Chromosome 17 in Chronic Lymphocytic Leukemia (B-CLL).. *Blood*, **2005**, 106, 3255-3255	2.2
77	Molecular and Clinical Analysis of a Midwest Cohort of B-CLL Patients Utilizing the Immunoglobulin VH 1-69 Gene.. *Blood*, **2005**, 106, 5016-5016	2.2
76	Long Term Follow up of Allogeneic Hematopoietic Stem Cell Transplantation (ASCT) in Chronic Lymphocytic Leukemia (CLL).. *Blood*, **2005**, 106, 5420-5420	2.2
75	Targeting Vla-4 Reduces Cell Adhesion Mediated Drug Resistance in Chronic Lymphocytic Leukemia: Rationale for Anti Vla-4 Therapy.. *Blood*, **2005**, 106, 1182-1182	2.2
74	Submicroscopic Interstitial Deletions in 13q14 Are Detectable in Metaphase Cells by Fluorescence In Situ Hybridization (FISH) with D13S319 in Chronic Lymphocytic Leukemia (B-CLL).. *Blood*, **2005**, 106, 3278-3278	2.2
73	Elevated HIF-1α Levels in CLL B Cells May Explain Their Autocrine VEGF Secretion.. *Blood*, **2006**, 108, 583-583	2.2
72	Inhibition of GSK-3 Induces Apoptosis of CLL Cells by Abrogating NFkB Nuclear Activity.. *Blood*, **2006**, 108, 2797-2797	2.2
71	A Large Scale Evaluation of Genetic Variation in Immune and Inflammation Genes and Risk of Non-Hodgkin Lymphoma.. *Blood*, **2006**, 108, 817-817	2.2
70	Neuropilin-1 Receptor (NRP-1) Occupancy Induces Cell Death in Primary Chronic Lymphocytic Leukemia (CLL) B Cells.. *Blood*, **2006**, 108, 586-586	2.2

69	Expression and Functional Analysis of Activation-Induced Deaminase (AID) in Normal Human B Lymphocytes.. *Blood*, **2006**, 108, 934-934	2.2
68	D Gene Usage Predicts Clinical Outcome in Patients with Low Rai Risk Unmutated B-CLL.. *Blood*, **2006**, 108, 2779-2779	2.2
67	Crosstalk between Chronic Lymphocytic Leukemia (CLL) B-Cells and Marrow Stromal Cells: Implication for CLL B-Cell Activation and Survival.. *Blood*, **2007**, 110, 337-337	2.2
66	The Prognostic Significance of Cytopenia in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL).. *Blood*, **2007**, 110, 746-746	2.2
65	Dietary Products Induce Apoptosis in CLL B Cells and Reveal Potential as a Therapeutic Combination That Can Overcome Stromal Cell Mediated Protection.. *Blood*, **2007**, 110, 3130-3130	2.2
64	Characterization of Microvesicles in B-Cell Chronic Lymphocytic Leukemia (CLL): A Potential Mediator in CLL B Cell Disease Progression?.. *Blood*, **2007**, 110, 747-747	2.2
63	Statin Use and Risk of Non-Hodgkin Lymphoma (NHL): Preliminary Results from the Mayo Clinic Case-Control Study.. *Blood*, **2007**, 110, 2615-2615	2.2
62	Clinical and Serological Characteristics of Cold Autoimmune Hemolytic Anemia with Concomitant Cold Agglutinin and Donath-Landsteiner Antibodies. *Blood*, **2017**, 130, 927-927	2.2
61	Telomere Length Is Associated with Epigenetic Programming in CLL and Is a Superior Predictor of Clinical Outcome with the Ability to Bifurcate Patients with the Same CLL-IPI Score. *Blood*, **2018**, 132, 1833-1833	2.2
60	Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Chronic Lymphocytic Leukemia (CLL) Driver Genes: Risk of CLL and Monoclonal B-Cell Lymphocytosis (MBL). *Blood*, **2018**, 132, 3116-3116	2.2
59	Size Matters: Identification of Larger Size CD19 Positive Extracellular Vesicles in Chronic Lymphocytic Leukemia That Inhibit Chimeric Antigen Receptor T Cell Functions. *Blood*, **2018**, 132, 1865-1865	2.2
58	Enhanced Expression of Beta-Catenin and Axl Receptor Tyrosine Kinase (RTK) in Chronic Lymphocytic Leukemia (CLL) B-Cells with Co-Culture on Marrow Stromal Cells: Implications for Leukemic Cell Drug Resistance. *Blood*, **2018**, 132, 3125-3125	2.2
57	Clinical Characteristics and Outcomes of Chronic Lymphocytic Leukemia Patients with Richter Transformation. *Blood*, **2018**, 132, 1857-1857	2.2
56	Bone Marrow Hematopoietic Dysfunction in Untreated Chronic Lymphocytic Leukemia Is Partially Mediated By Exposure to Constituents of the Leukemic Microenvironment. *Blood*, **2018**, 132, 3132-3132	2.2
55	A Laboratory Based Scoring System Predicts Early Treatment in Rai 0/Binet a CLL. *Blood*, **2018**, 132, 4399-4399	2.2
54	Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmunotherapy. *Blood*, **2018**, 132, 4394-4394	2.2
53	Association between the Risk of Low/High-Count Monoclonal B-Cell Lymphocytosis (MBL) and the Chronic Lymphocytic Leukemia (CLL) Polygenic Risk Score (PRS). *Blood*, **2018**, 132, 5538-5538	2.2
52	Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis. *Blood*, **2019**, 134, 3022-3022	2.2

51	A Role for TNF-□n Chronic Lymphocytic Leukemia Bone Marrow Hematopoietic Dysfunction. *Blood*, **2019**, 134, 4276-4276	2.2
50	□Catenin and Axl Receptor Tyrosine Kinase Modulation in CLL B-Cells with Co-Culture on Marrow Stromal Cells: Implications for Drug Resistance. *Blood*, **2019**, 134, 1739-1739	2.2
49	Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphocytosis (MBL). *Blood*, **2019**, 134, 852-852	2.2
48	The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis. *Blood*, **2019**, 134, 3037-3037	2.2
47	Correlation Between Peripheral Blood Counts and Extent of Bone Marrow Infiltration in Chronic Lymphocytic Leukemia. *Blood*, **2015**, 126, 2926-2926	2.2
46	Reasons for Initiation of First-Line Therapy and Early Outcomes for Patients (Pts) with Rai 0/1 Chronic Lymphocytic Leukemia (CLL): An Analysis of the Connect CLL□ Cohort Study. *Blood*, **2015**, 126, 3284-3284	2.2
45	A Comprehensive Progression Risk Score to Predict Treatment Free Survival for Early Stage Chronic Lymphocytic Leukemia Patients. *Blood*, **2015**, 126, 2930-2930	2.2
44	Treatment Selection and Practice Patterns for the Management of High-Risk Chronic Lymphocytic Leukemia (CLL) in the US: An Analysis of the Impact of Risk Stratification on Treatment Selection from the Connect CLL□ Registry. *Blood*, **2015**, 126, 4483-4483	2.2
43	Mutations in Driver Genes and Changes in Clonal Dynamics Are Associated with Shorter Time to Treatment in MBL Cases. *Blood*, **2015**, 126, 5264-5264	2.2
42	Analysis of Early Mortality of Chronic Lymphocytic Leukemia (CLL) Patients Treated in US Practices in the Connect CLL□ Registry. *Blood*, **2015**, 126, 5270-5270	2.2
41	Sensitivity of Ibrutinib Exposed Chronic Lymphocytic Leukemia B-Cells to Inhibition of Axl Receptor Tyrosine Kinase. *Blood*, **2016**, 128, 2020-2020	2.2
40	Novel Associations Between Mutations, Prognostic and Clinical Parameters in Untreated Progressive CLL: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group. *Blood*, **2016**, 128, 4373-4373	2.2
39	Liver Dysfunction in Previously Untreated Chronic Lymphocytic Leukemia: Prevalence and Outcomes in a Large Cohort. *Blood*, **2016**, 128, 5585-5585	2.2
38	The Role of Splenectomy in the Care and Treatment of the CLL Patient. *Blood*, **2016**, 128, 5575-5575	2.2
37	Characteristics of Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Receiving Rituximab Monotherapy in the Connect□ CLL Registry. *Blood*, **2016**, 128, 5941-5941	2.2
36	Epigenetic Silencing of Catalase Induces Accumulation of Reactive Oxygen Species in Chronic Lymphocytic Leukemia B Cells Leading to Activation of Axl: An Escape Strategy?. *Blood*, **2016**, 128, 4363-4363	2.2
35	Bone Marrow (BM) Hematopoietic Dysfunction in Chronic Lymphocytic Leukemia (CLL) - Association with Leukemic Burden and Reversibility with Therapeutic Responses.. *Blood*, **2016**, 128, 2013-2013	2.2
34	Clinically Ascertained Monoclonal B-Cell Lymphocytosis: Risk of Progression to Chronic Lymphocytic Leukemia Requiring Therapy and Outcomes. *Blood*, **2016**, 128, 3228-3228	2.2

33	Platelet-Derived Growth Factor (PDGF) Secreted by Chronic Lymphocytic Leukemic B-Cells Is Capable of Regulating the Activation and Function of Mesenchymal Stem Cells: Implications for Leukemic Cell/Stromal Cell Crosstalk. *Blood*, **2008**, 112, 355-355	2.2
32	Validation of CLL FISH Panel Scoring by Members of the Chronic Lymphocytic Leukemia Research Consortium.. *Blood*, **2008**, 112, 1067-1067	2.2
31	Higher Intakes of Vegetables, Vitamin E, Manganese and Zinc Are Associated with a Lower Risk of Non-Hodgkin Lymphoma (NHL): Results from a Case-Control Study. *Blood*, **2008**, 112, 3771-3771	2.2
30	Whole Genome Copy Number Variation Analysis of Chronic Lymphocytic Leukemia (CLL) Cells From Early-Intermediate Stage, High Risk CLL Patients Prior to First Treatment Reveals New Loss of Heterozygosity and Duplication Events in the CLL Genome.. *Blood*, **2009**, 114, 1265-1265	2.2
29	Aberrant Regulation of the LEF-1 Locus in Monoclonal B Cell Lymphocytosis (MBL) and Chronic Lymphocytic Leukemia (CLL): A Possible Role for Epigenetic Regulation.. *Blood*, **2009**, 114, 669-669	2.2
28	Complex Interstitial Deletions of 11q and Copy-Neutral Loss of Heterozygosity of 11q Are Detected by Whole Genome Copy Number Variation Analysis of Early-Intermediate Stage, High Risk Chronic Lymphocytic Leukemia Patients.. *Blood*, **2009**, 114, 1245-1245	2.2
27	Longitudinal Genome Wide Analysis of Patients with Chronic Lymphocytic Leukemia Reveals Complex Evolution of Clonal Architecture At Disease Progression and At the Time of Relapse. *Blood* , **2011**, 118, 2838-2838	2.2
26	Infectious Complications Among Individuals with Monoclonal B-Cell Lymphocytosis (MBL): A Prospective Case-Control Study of Newly Diagnosed Patients,. *Blood*, **2011**, 118, 3903-3903	2.2
25	Global Genomic Status At Diagnosis Informs Clinical Outcome in B-Chronic Lymphocytic Leukemia: Stable Versus Progressive Disease. *Blood*, **2011**, 118, 1772-1772	2.2
24	Ofatumumab Based Chemoimmunotherapy (CIT) for Patients with Previously Untreated CLL,. *Blood* , **2011**, 118, 3898-3898	2.2
23	Prevalence of MBL Increases Over Time In Relatives of CLL Families,. *Blood*, **2011**, 118, 3881-3881	2.2
22	Alemtuzumab Use and Survival After Reduced Intensity Allogeneic Stem Cell Transplantation in High-Risk Chronic Lymphocytic Leukemia (CLL),. *Blood*, **2011**, 118, 4152-4152	2.2
21	TRIS (DIBENZYLIDENEACETONE) Dipalladium a Small-Molecule Palladium Complex Is Effective in the Induction of Apoptosis for B-Chronic Lymphocytic Leukemia B-Cells. *Blood*, **2011**, 118, 2851-2851	2.2
20	Epigallocatechin-3-Gallate (EGCG) Modulates Cytokine Production When Leukemic CLL B-Cells and Marrow Stromal Cells Are Co-Cultured: Correlations with Clinical Activity in a Phase II Trial,. *Blood*, **2011**, 118, 3882-3882	2.2
19	Variation in Health-Related Quality of Life by Age Among Patients with Chronic Lymphocytic Leukemia. *Blood*, **2011**, 118, 2085-2085	2.2
18	Mesenchymal Stromal Cells Derived From Chronic Lymphocytic Leukemic Patients Express Different Genes and Produce Different Cytokines Compared to MSC Derived From Normal Subjects,. *Blood*, **2011**, 118, 3872-3872	2.2
17	The Prevalence of Serious Infectious Complications in a Cohort of Non-Referred Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) Compared to Controls: Results of a Cohort Study. *Blood*, **2011**, 118, 4610-4610	2.2
16	FISH Scoring for CLL: Comparison of Methods That Assess Round Versus Non-Round Nuclei,. *Blood*, **2011**, 118, 3538-3538	2.2

List of Publications

15	Allosteric Akt Inhibitor MK2206 Synergizes with Bendamustine in Promoting the Apoptosis of Chronic Lymphocytic Leukemia Cells and Selectively Targets B-Cell Receptor Mediated Cytokine Production. *Blood*, **2012**, 120, 3928-3928	2.2
14	Very High Risk CLL Characterized by a Double Hit Clone with Both 11q22 and 17p13 Deletion.. *Blood*, **2012**, 120, 2486-2486	2.2
13	The Impact of Race, Age, and Sex in Chronic Lymphocytic Leukemia (CLL): A Comprehensive SEER Analysis in the Pre and Post Rituximab (R) Eras.. *Blood*, **2012**, 120, 2877-2877	2.2
12	Novel Pharmacological Agents Differentially Modulate Cytokine Release On CLL B-Cell-Stromal Cell Co-Culture: Implications for Stromal Rescue of CLL B-Cells From Chemotherapy. *Blood*, **2012**, 120, 3927-3927	2.2
11	Risk of Cancer in Patients with Clinical Monoclonal B-Cell Lymphocytosis (MBL): A Cohort Study of Newly Diagnosed Patients Compared to Controls.. *Blood*, **2012**, 120, 2893-2893	2.2
10	Clonal Chromosomal Anomalies Similar to CLL and Other Hematologic Malignancies Can Be Found in Normal Individuals. *Blood*, **2012**, 120, 873-873	2.2
9	Extramedullary Chronic Lymphocytic Leukemia: Systematic Analysis of Cases Reported Between 1975 and 2010. *Blood*, **2012**, 120, 4607-4607	2.2
8	Chronic Lymphocytic Leukemia in Young (≤55 years) Patients: A Comprehensive Analysis of Prognostic Factors and Outcomes.. *Blood*, **2012**, 120, 2901-2901	2.2
7	The Relative Significance of ZAP-70 Promoter Methylation As a Prognostic Factor in Previously Untreated Chronic Lymphocytic Leukemia: Validation of Results Using a Second Large CLL Research Consortium (CRC) Patient Data Set. *Blood*, **2012**, 120, 3865-3865	2.2
6	Transformation of Chronic Lymphocytic Leukemia Into Diffuse Large B-Cell Lymphoma (Richter's Syndrome): Large Retrospective Analysis From a Single Institution.. *Blood*, **2012**, 120, 2902-2902	2.2
5	Analysis of Stem Cell Transplant Referral in a Cohort of Newly Diagnosed Chronic Lymphocytic Leukemia Patients. *Blood*, **2012**, 120, 4252-4252	2.2
4	Genomic Landscape and Clonal Heterogeneity Underlying Progression and Relapse In Chronic Lymphocytic Leukemia (CLL). *Blood*, **2013**, 122, 2855-2855	2.2
3	Chronic Graft Vs Host Disease Is The Strongest Predictor Of Outcome After Reduced Intensity Conditioning Stem Cell Transplantation In Chronic Lymphocytic Leukemia and Is Associated With Pretransplant B Cell Characteristics. *Blood*, **2013**, 122, 3375-3375	2.2
2	The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087 Alliance). *Blood*, **2013**, 122, 2882-2882	2.2
1	Upregulation of AXL and β-catenin in chronic lymphocytic leukemia cells cultured with bone marrow stroma cells is associated with enhanced drug resistance. *Blood Cancer Journal*, **2021**, 11, 37	7